At present, several ALK inhibitors, including crizotinib, alectinib, ceritinib, brigatinib, ensartinib, and lorlatinib, have been approved as standard therapy for ALK-p NSCLC [1,3,17]. Here, ALK is linked to non-small cell lung carcinoma.